PTPaolo A. Tomasi

Paolo A. Tomasi

*This is an algorithmically generated author record based on publicly available information.

Paolo A. Tomasi has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study

    by Thomas J Hwang, Paolo A Tomasi, Florence T Bourgeois

    Few medicines have been approved for children, leading to rates of off-label prescribing reported to be as high as 90%. In 2007, the European Union adopted the Paediatric Regulation, which mandates that pharmaceutical companies conduct paediatric studies for all new medicines, unless granted a waiver. We aimed to evaluate the availability of paediatric trial results from studies required under the Paediatric Regulation for new medicines authorised in the EU. The European Medicines Agency (EMA) public database of paediatric investigation plans was searched for new medicines centrally authorised in the EU between 1 January 2010 and 31 December 2014 with at least 1 required paediatric study. For our study cohort of paediatric clinical trials required for these medicines, we used internal EMA databases and publicly available trial registries to determine changes to the planned completion date or study design, rates of trial completion, time to trial completion, and results reporting (peer-reviewed publication or posting on trial registry). Cox proportional hazards regression models were constructed to examine factors associated with study completion. A total of 326 paediatric clinical trials were required for 122 novel medicines authorised by the EMA between 2010 and 2014. In all, 76% (247/326) of paediatric studies were not planned to be completed until after the initial marketing authorisation. The planned completion dates for 50% (162/326) were further postponed by a median of 2.2 years. Overall, 38% (124/326) of paediatric studies were completed as of 30 November 2017. The rate of trial completion for paediatric studies planned to be completed after initial marketing authorisation was 23% (56/247), versus 86% (68/79) for trials planned to be completed before authorisation (adjusted hazard ratio 0.11; 95% CI 0.06–0.19). Among completed studies, the results were reported in a public registry or in the peer-reviewed literature for 85% (105/124) at a median of 1.1 years after study completion, and 60% (74/124) were published in a peer-reviewed journal. Limitations of this study include the potential lack of generalisability to medicines not authorised by the EMA and the possibility for more of these trials to be completed or published in the future. The completion of many paediatric studies required under the Paediatric Regulation has been delayed. Paediatric studies planned to be completed after marketing authorisation were associated with a lower likelihood of eventual completion, highlighting the need to examine the implementation of current policies in ensuring timely availability of important paediatric information.


  • More medicines for children: impact of the EU paediatric regulation

    by Sofia Nordenmalm, Paolo Tomasi, Chrissi Pallidis

    Introduction This paper focuses on the authorisation of new medicines, new indications and new pharmaceutical forms or strengths for use in children and also on the availability of paediatric information in the product information of centrally authorised medicinal products following the enforcement of the Paediatric Regulation on 26 January 2007. Objectives To investigate whether the Paediatric Regulation has led to more medicines available for children in the European Union (EU) and if more information on paediatric use is now available in the product information of medicines authorised via the centralised procedure. Materials and methods We retrospectively analysed the centrally authorised medicinal products in the EU that had an approval for an initial marketing authorisation, a type II variation, or a line extension during the years 2004–2006 and 2012–2014. Medicinal products not subjected to the obligations of the Paediatric Regulation were excluded. Results In 2004–2006, 20 new medicines and 10 new indications were centrally authorised for paediatric use compared with 26 new medicines and 37 new indications in 2012–2014. The number of medicines with a new pharmaceutical form or strength for use in children was eight in 2004–2006 and seven in 2012–2014. There was a huge increase in the number of products with changes of paediatric relevance in the summary of product characteristics in 2012–2014 compared with 2004–2006. Conclusions The entry into force of the Paediatric Regulation has had a positive impact on paediatric drug development with more medicines available for children in the EU and substantially more information available for clinicians on paediatric use in the product information.


  • Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations

    by Andrea Ecker, Segundo Mariz, Frauke Naumann-Winter, Koenraad Norga, Ingeborg Barisic, Thomas Girard, Paolo Tomasi, Dirk Mentzer, Bruno Sepodes

    Background Market forces may not be sufficient to stimulate research and development of medicines for small patient populations, such as children and patients with rare diseases. Both the European Union Orphan and Paediatric Regulations were introduced to address the unmet public health needs of these smaller patient populations through the use of incentives, rewards and obligations. Developers for new medicines for rare diseases must agree a paediatric investigation plan (PIP) or waiver with the European Medicines Agency’s (EMA) Paediatric Committee (PDCO), and can also apply for an orphan designation (OD) from the EMA’s Committee of Orphan Medicinal Products (COMP). The scope of both the OD and the PIP (or waiver) is defined by the agreed condition. Objectives The aim of this study was to analyse the approach of PDCO and COMP in defining the appropriate condition for a PIP or OD, respectively, in order to investigate potential challenges in the paediatric development of orphan medicines which have to meet the requirements of both legislations. Methods A comparative analysis of PIP conditions and OD conditions was performed for medicines that have been reviewed by both Committees. Results We found that in the substantial majority of cases there is no divergence between the conclusions of COMP and PDCO with regard to the condition for which a medicine is to be developed. Conclusion These findings demonstrate that a collaborative approach allows both Regulations to work synergistically to foster pharmaceutical development for rare diseases in childhood.


  • Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation

    by Paolo A. Tomasi, Gunter F. Egger, Chrissi Pallidis, Agnes Saint-Raymond

    The year 2017 marks the tenth anniversary of entry into force of the Paediatric Regulation in the European Union (EU). This law aimed to stimulate the development of paediatric medicines and provide more information on their use, as a response to the lack of evidence and approval of medicines for children. The European Medicines Agency (EMA) has had a central role in the implementation of the Regulation. Pharmaceutical companies need to submit a paediatric investigation plan (PIP) to the EMA’s Paediatric Committee (PDCO) for every new medicine, unless an exemption (waiver) is granted. The plans, which describe the development of drugs for children, must be agreed well in advance of the request for marketing authorization of the medicine. Deferrals of studies can be granted to allow approval in adults before the completion of paediatric studies. Between January 2007 and December 2016, a total of 273 new medicines and 43 additional pharmaceutical forms appropriate for use in children were authorized in the EU, and 950 PIPs were agreed by the EMA. In addition, 486 waivers of the development of a medicine in one or more medical conditions were agreed. The Paediatric Regulation has had a very positive impact on paediatric drug development, as exemplified by a comparison of two periods of 3 years before and after entry into force of the Regulation. We conclude that the Regulation has resulted in more medicines for children and more information on the pediatric use of medicines in the EU being available to clinicians.


  • Pediatric Medicine Development: An Overview and Comparison of Regulatory Processes in the European Union and United States

    by Dobromir Penkov, Paolo Tomasi, Irmgard Eichler, Dianne Murphy, Lynne P. Yao, Jean Temeck

    Pediatric legislation in the US and the EU is driving pediatric product development on an international scale. To facilitate harmonization and global devel


  • Scaling Dose-Exposure-Response from Adults to Children

    by Ine Skottheim Rusten, Anna Nordmark, Susan Cole, Joseph F. Standing, Sofia Friberg Hietala, Wei Zhao, Valeria Gigante, Anna Karin Hamberg, Gérard Pons, María Jesús Garrido, et al.


  • A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007–2013

    by Gunter F. Egger, Gerold T. Wharton, Suzanne Malli, Jean Temeck, M. Dianne Murphy, Paolo Tomasi

    The European Union and the United States have different legal frameworks in place for pediatric drug development, which can potentially lead to different p


  • Important issues in the justification of a control treatment in paediatric drug trials

    by Lauren E Kelly, Elin Haf Davies, Agnes Saint-Raymond, Paolo Tomasi, Martin Offringa

    ObjectiveThe value of comparative effectiveness trials in informing clinical and policy decisions depends heavily on the choice of control arm (comparator). Our objective is to identify challenges in comparator reasoning and to determine justification criteria for selecting a control arm in paediatric clinical trials.DesignA literature search was completed to identify existing sources of guidance on comparator selection. Subsequently, we reviewed a randomly selected sample of comparators selected for paediatric investigation plans (PIPs) adopted by the Paediatric Committee of the European Medicines Agency in 2013. We gathered descriptive information and evaluated their review process to identify challenges and compromises between regulators and sponsors with regard to the selection of the comparator. A tool to help investigators justify the selection of active controls and placebo arms was developed using the existing literature and empirical data.ResultsJustifying comparator selection was a challenge in 28% of PIPs. The following challenging paediatric issues in the decision-making process were identified: use of off-label medications as comparators, ethical and safe use of placebo, duration of placebo use, an undefined optimal dosing strategy, lack of age-appropriate safety and efficacy data, and drug dosing not supported by extrapolation of safety/efficacy evidence from other populations.ConclusionsIn order to generate trials that will inform clinical decision-making and support marketing authorisations, researchers must systemically and transparently justify their selection of the comparator arm for their study. This report highlights key areas for justification in the choice of comparator in paediatric clinical trials.


  • Open Access

    Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions

    by William V. Tamborlane, Morey W. Haymond, David Dunger, Ravi Shankar, Rose Gubitosi-Klug, Kathleen Bethin, Janina Karres, Paolo Tomasi, Ingrid Libman, Paula H. Hale, et al.

    The Best Pharmaceuticals for Children Act of 2002 mandated that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) carr


  • Neonatal Pharmacotherapy: Legal and Regulatory Issues

    by Ralph Bax, Paolo Tomasi

    Off-label and unlicensed use of medicines is high in the paediatric population and specifically high in neonatal/paediatric intensive settings with up to 90% of cases. This is associated with higher incidence and severity of adverse drug reactions and can be addressed by including all paediatric age groups including neonates into clinical trials to ensure safety and efficacy of the medicine together with a formulation appropriate for the neonate. Legislation has been introduced in the US and the EU to request this development. A number of supporting scientific guidelines, network and further legal/regulatory initiatives are ongoing and have led to an increase of studies planned for neonates. However, even more efforts specifically for the most vulnerable and heterogeneous population of preterm infants is needed.